Sesen Bio downgraded by HC Wainwright & Co.

Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact th

Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. In reaching its concl

Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio's Largest Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Compan

HC Wainwright & Co. downgraded Sesen Bio from Buy to Neutral

Canaccord Genuity resumed coverage of Sesen Bio with a rating of Buy and set a new price target of $7.00

HC Wainwright reiterated coverage of Sesen Bio with a rating of Buy and set a new price target of $8.00 from $2.25 previously

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

4 - Carisma Therapeutics Inc. (0001485003) (Issuer)

10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

8-K - Carisma Therapeutics Inc. (0001485003) (Filer)

Company hires four experienced leaders across commercial, medical and human resources functions as it works towards launch readiness Company remains on track for potential approval of Vicineum™ in the US in August 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its senior leadership team with the appointment of experienced industry leaders to several key roles: Patricia Drake to Chief Commercial Officer Steve Barbera to Vice President, Market Access Julie Hoff to Vice President, Human Resources Dewey McLin to Vice President, Medical Affairs "I a

Company appoints experienced commercial leader, Lisa LaMond, to oversee sales strategy and execution Selected Syneos Health® as partner for field sales execution in the US Company remains on track for potential approval in the US in August 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced commercial industry leader, Lisa LaMond, as Vice President, Sales and Corporate Systems. The Company also announced its engagement of leading contract sales organization (CSO), Syneos Health, for field sales support

Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact th

Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. In reaching its concl

Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio's Largest Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Compan

SC 13G/A - Carisma Therapeutics Inc. (0001485003) (Subject)

SC 13G/A - Carisma Therapeutics Inc. (0001485003) (Subject)

SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)